{"entity":{"type":"insider","cik":"0001366244","url":"/insider/0001366244","json_url":"/insider/0001366244.json","name":"Palleiko Benjamin L","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":43,"n_filings":39,"first":"2007-09-14","last":"2026-05-26","span_basis":"filed_date"},"name_variants":[{"name":"Palleiko Benjamin L","source":"filing","n_filings":39,"first_seen":"2007-09-14","last_seen":"2026-05-26"}],"transactions":[{"id":5800067,"accession":"0001366244-26-000010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366244-26-000010","line_url":"/filing/0001366244-26-000010#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10926.0,"shares_display":"10,926","price_per_share":26.7844,"price_display":"26.78","price_state":"stated","total_value":292646.3544,"total_display":"292,646.35","total_whole":"292,646","shares_owned_after":479989.0,"shares_owned_after_display":"479,989","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-22","filed_date":"2026-05-26","scope":"insider"},{"id":6156664,"accession":"0001366244-26-000009","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366244-26-000009","line_url":"/filing/0001366244-26-000009#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1129.0,"shares_display":"1,129","price_per_share":26.76,"price_display":"26.76","price_state":"stated","total_value":30212.04,"total_display":"30,212.04","total_whole":"30,212","shares_owned_after":467665.0,"shares_owned_after_display":"467,665","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-18","filed_date":"2026-05-19","scope":"insider"},{"id":5874821,"accession":"0001366244-26-000007","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366244-26-000007","line_url":"/filing/0001366244-26-000007#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3322.0,"shares_display":"3,322","price_per_share":26.71,"price_display":"26.71","price_state":"stated","total_value":88730.62,"total_display":"88,730.62","total_whole":"88,731","shares_owned_after":466375.0,"shares_owned_after_display":"466,375","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-12","filed_date":"2026-05-13","scope":"insider"},{"id":5861470,"accession":"0001366244-26-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366244-26-000006","line_url":"/filing/0001366244-26-000006#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9550.0,"shares_display":"9,550","price_per_share":20.2163,"price_display":"20.22","price_state":"stated","total_value":193065.665,"total_display":"193,065.66","total_whole":"193,066","shares_owned_after":462577.0,"shares_owned_after_display":"462,577","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-17","filed_date":"2026-04-20","scope":"insider"},{"id":5986062,"accession":"0001366244-26-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366244-26-000005","line_url":"/filing/0001366244-26-000005#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6693.0,"shares_display":"6,693","price_per_share":16.0814,"price_display":"16.08","price_state":"stated","total_value":107632.8102,"total_display":"107,632.81","total_whole":"107,633","shares_owned_after":451815.0,"shares_owned_after_display":"451,815","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-09","filed_date":"2026-03-10","scope":"insider"},{"id":5800064,"accession":"0001366244-26-000004","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366244-26-000004","line_url":"/filing/0001366244-26-000004#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10034.0,"shares_display":"10,034","price_per_share":15.5668,"price_display":"15.57","price_state":"stated","total_value":156197.2712,"total_display":"156,197.27","total_whole":"156,197","shares_owned_after":442883.0,"shares_owned_after_display":"442,883","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-23","filed_date":"2026-02-24","scope":"insider"},{"id":5764923,"accession":"0001366244-26-000003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366244-26-000003","line_url":"/filing/0001366244-26-000003#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1038.0,"shares_display":"1,038","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":15570.0,"total_display":"15,570.00","total_whole":"15,570","shares_owned_after":429667.0,"shares_owned_after_display":"429,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-18","filed_date":"2026-02-19","scope":"insider"},{"id":5965990,"accession":"0001366244-26-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366244-26-000002","line_url":"/filing/0001366244-26-000002#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3354.0,"shares_display":"3,354","price_per_share":15.7,"price_display":"15.70","price_state":"stated","total_value":52657.8,"total_display":"52,657.80","total_whole":"52,658","shares_owned_after":428286.0,"shares_owned_after_display":"428,286","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-12","filed_date":"2026-02-13","scope":"insider"},{"id":4705218,"accession":"0001366244-25-000007","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366244-25-000007","line_url":"/filing/0001366244-25-000007#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7294.0,"shares_display":"7,294","price_per_share":16.51,"price_display":"16.51","price_state":"stated","total_value":120423.94,"total_display":"120,423.94","total_whole":"120,424","shares_owned_after":424520.0,"shares_owned_after_display":"424,520","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-08","filed_date":"2025-12-09","scope":"insider"},{"id":5191756,"accession":"0001366244-25-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366244-25-000006","line_url":"/filing/0001366244-25-000006#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10940.0,"shares_display":"10,940","price_per_share":13.451,"price_display":"13.45","price_state":"stated","total_value":147153.94,"total_display":"147,153.94","total_whole":"147,154","shares_owned_after":416189.0,"shares_owned_after_display":"416,189","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-24","filed_date":"2025-11-26","scope":"insider"},{"id":4804111,"accession":"0001366244-25-000004","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366244-25-000004","line_url":"/filing/0001366244-25-000004#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4466.0,"shares_display":"4,466","price_per_share":14.4794,"price_display":"14.48","price_state":"stated","total_value":64665.0004,"total_display":"64,665.00","total_whole":"64,665","shares_owned_after":403879.0,"shares_owned_after_display":"403,879","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-18","filed_date":"2025-11-19","scope":"insider"},{"id":5001803,"accession":"0001366244-25-000003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366244-25-000003","line_url":"/filing/0001366244-25-000003#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3328.0,"shares_display":"3,328","price_per_share":11.55,"price_display":"11.55","price_state":"stated","total_value":38438.4,"total_display":"38,438.40","total_whole":"38,438","shares_owned_after":398981.0,"shares_owned_after_display":"398,981","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-12","filed_date":"2025-11-13","scope":"insider"},{"id":4953356,"accession":"0001415889-25-024009","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-024009","line_url":"/filing/0001415889-25-024009#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7294.0,"shares_display":"7,294","price_per_share":15.84,"price_display":"15.84","price_state":"stated","total_value":115536.96,"total_display":"115,536.96","total_whole":"115,537","shares_owned_after":395189.0,"shares_owned_after_display":"395,189","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-08","filed_date":"2025-09-09","scope":"insider"},{"id":4036708,"accession":"0001415889-25-022965","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-022965","line_url":"/filing/0001415889-25-022965#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10940.0,"shares_display":"10,940","price_per_share":13.2228,"price_display":"13.22","price_state":"stated","total_value":144657.432,"total_display":"144,657.43","total_whole":"144,657","shares_owned_after":386858.0,"shares_owned_after_display":"386,858","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-22","filed_date":"2025-08-25","scope":"insider"},{"id":4383479,"accession":"0001415889-25-022304","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-022304","line_url":"/filing/0001415889-25-022304#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4409.0,"shares_display":"4,409","price_per_share":13.187,"price_display":"13.19","price_state":"stated","total_value":58141.483,"total_display":"58,141.48","total_whole":"58,141","shares_owned_after":374548.0,"shares_owned_after_display":"374,548","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-19","scope":"insider"},{"id":4920370,"accession":"0001415889-25-019657","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-019657","line_url":"/filing/0001415889-25-019657#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":32979.0,"shares_display":"32,979","price_per_share":15.6925,"price_display":"15.69","price_state":"stated","total_value":517522.9575,"total_display":"517,522.96","total_whole":"517,523","shares_owned_after":369595.0,"shares_owned_after_display":"369,595","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-09","filed_date":"2025-07-10","scope":"insider"},{"id":4861750,"accession":"0001415889-25-016522","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-016522","line_url":"/filing/0001415889-25-016522#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7169.0,"shares_display":"7,169","price_per_share":14.5,"price_display":"14.50","price_state":"stated","total_value":103950.5,"total_display":"103,950.50","total_whole":"103,951","shares_owned_after":315074.0,"shares_owned_after_display":"315,074","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-09","filed_date":"2025-06-10","scope":"insider"},{"id":4382658,"accession":"0001415889-25-014474","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-014474","line_url":"/filing/0001415889-25-014474#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9999.0,"shares_display":"9,999","price_per_share":11.8755,"price_display":"11.88","price_state":"stated","total_value":118743.1245,"total_display":"118,743.12","total_whole":"118,743","shares_owned_after":306618.0,"shares_owned_after_display":"306,618","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-22","filed_date":"2025-05-23","scope":"insider"},{"id":4211433,"accession":"0001415889-25-013869","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-013869","line_url":"/filing/0001415889-25-013869#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3808.0,"shares_display":"3,808","price_per_share":11.8428,"price_display":"11.84","price_state":"stated","total_value":45097.3824,"total_display":"45,097.38","total_whole":"45,097","shares_owned_after":293367.0,"shares_owned_after_display":"293,367","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-19","filed_date":"2025-05-20","scope":"insider"},{"id":4036005,"accession":"0001415889-25-007589","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-007589","line_url":"/filing/0001415889-25-007589#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6669.0,"shares_display":"6,669","price_per_share":11.97,"price_display":"11.97","price_state":"stated","total_value":79827.93,"total_display":"79,827.93","total_whole":"79,828","shares_owned_after":287811.0,"shares_owned_after_display":"287,811","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-07","filed_date":"2025-03-10","scope":"insider"},{"id":4706674,"accession":"0001415889-25-004771","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-004771","line_url":"/filing/0001415889-25-004771#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5104.0,"shares_display":"5,104","price_per_share":9.8242,"price_display":"9.82","price_state":"stated","total_value":50142.7168,"total_display":"50,142.72","total_whole":"50,143","shares_owned_after":278855.0,"shares_owned_after_display":"278,855","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-18","filed_date":"2025-02-19","scope":"insider"},{"id":2449832,"accession":"0001415889-24-028746","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-028746","line_url":"/filing/0001415889-24-028746#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7627.0,"shares_display":"7,627","price_per_share":9.75,"price_display":"9.75","price_state":"stated","total_value":74363.25,"total_display":"74,363.25","total_whole":"74,363","shares_owned_after":274596.0,"shares_owned_after_display":"274,596","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-09","filed_date":"2024-12-09","scope":"insider"},{"id":2102618,"accession":"0001415889-24-027274","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-027274","line_url":"/filing/0001415889-24-027274#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14400.0,"shares_display":"14,400","price_per_share":9.2565,"price_display":"9.26","price_state":"stated","total_value":133293.6,"total_display":"133,293.60","total_whole":"133,294","shares_owned_after":266598.0,"shares_owned_after_display":"266,598","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-18","filed_date":"2024-11-19","scope":"insider"},{"id":2044100,"accession":"0001415889-24-023183","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-023183","line_url":"/filing/0001415889-24-023183#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7352.0,"shares_display":"7,352","price_per_share":12.1901,"price_display":"12.19","price_state":"stated","total_value":89621.6152,"total_display":"89,621.62","total_whole":"89,622","shares_owned_after":250800.0,"shares_owned_after_display":"250,800","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-09","filed_date":"2024-09-10","scope":"insider"},{"id":3237371,"accession":"0001415889-24-021969","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-021969","line_url":"/filing/0001415889-24-021969#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14215.0,"shares_display":"14,215","price_per_share":12.0133,"price_display":"12.01","price_state":"stated","total_value":170769.0595,"total_display":"170,769.06","total_whole":"170,769","shares_owned_after":242527.0,"shares_owned_after_display":"242,527","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-19","filed_date":"2024-08-21","scope":"insider"},{"id":2564110,"accession":"0001415889-24-016278","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-016278","line_url":"/filing/0001415889-24-016278#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7465.0,"shares_display":"7,465","price_per_share":11.5296,"price_display":"11.53","price_state":"stated","total_value":86068.464,"total_display":"86,068.46","total_whole":"86,068","shares_owned_after":224547.0,"shares_owned_after_display":"224,547","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-07","filed_date":"2024-06-10","scope":"insider"},{"id":3236506,"accession":"0001415889-24-014001","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-014001","line_url":"/filing/0001415889-24-014001#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF EXECUTIVE OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21959.0,"shares_display":"21,959","price_per_share":11.7645,"price_display":"11.76","price_state":"stated","total_value":258336.6555,"total_display":"258,336.66","total_whole":"258,337","shares_owned_after":216387.0,"shares_owned_after_display":"216,387","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-20","filed_date":"2024-05-21","scope":"insider"},{"id":2659185,"accession":"0001415889-24-004714","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-004714","line_url":"/filing/0001415889-24-004714#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (CFO, CBO)","role_mark":"O","role_mark_label":"Officer (CFO, CBO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO, CBO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22802.0,"shares_display":"22,802","price_per_share":14.1148,"price_display":"14.11","price_state":"stated","total_value":321845.6696,"total_display":"321,845.67","total_whole":"321,846","shares_owned_after":187315.0,"shares_owned_after_display":"187,315","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-20","filed_date":"2024-02-21","scope":"insider"},{"id":2188726,"accession":"0001415889-24-004123","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-004123","line_url":"/filing/0001415889-24-004123#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (CFO, CBO)","role_mark":"O","role_mark_label":"Officer (CFO, CBO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO, CBO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40855.0,"shares_display":"40,855","price_per_share":15.0093,"price_display":"15.01","price_state":"stated","total_value":613204.9515,"total_display":"613,204.95","total_whole":"613,205","shares_owned_after":159088.0,"shares_owned_after_display":"159,088","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-14","filed_date":"2024-02-16","scope":"insider"},{"id":8405941,"accession":"0001209191-23-056269","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-056269","line_url":"/filing/0001209191-23-056269#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (President, CFO, CBO & Sec'y)","role_mark":"O","role_mark_label":"Officer (President, CFO, CBO & Sec'y)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, CFO, CBO & Sec'y","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13008.0,"shares_display":"13,008","price_per_share":8.2293,"price_display":"8.23","price_state":"stated","total_value":107046.7344,"total_display":"107,046.73","total_whole":"107,047","shares_owned_after":112443.0,"shares_owned_after_display":"112,443","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-20","filed_date":"2023-11-21","scope":"insider"},{"id":8657803,"accession":"0001209191-23-046821","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-046821","line_url":"/filing/0001209191-23-046821#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (President, CFO, CBO & Sec'y)","role_mark":"O","role_mark_label":"Officer (President, CFO, CBO & Sec'y)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, CFO, CBO & Sec'y","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13067.0,"shares_display":"13,067","price_per_share":10.7287,"price_display":"10.73","price_state":"stated","total_value":140191.9229,"total_display":"140,191.92","total_whole":"140,192","shares_owned_after":95254.0,"shares_owned_after_display":"95,254","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-18","filed_date":"2023-08-21","scope":"insider"},{"id":8253750,"accession":"0001209191-23-031294","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-031294","line_url":"/filing/0001209191-23-031294#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (President, CFO, CBO & Sec'y)","role_mark":"O","role_mark_label":"Officer (President, CFO, CBO & Sec'y)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, CFO, CBO & Sec'y","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4037.0,"shares_display":"4,037","price_per_share":10.1444,"price_display":"10.14","price_state":"stated","total_value":40952.9428,"total_display":"40,952.94","total_whole":"40,953","shares_owned_after":78126.0,"shares_owned_after_display":"78,126","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-18","filed_date":"2023-05-19","scope":"insider"},{"id":8035231,"accession":"0001209191-23-012316","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-012316","line_url":"/filing/0001209191-23-012316#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (President, CFO, CBO & Sec'y)","role_mark":"O","role_mark_label":"Officer (President, CFO, CBO & Sec'y)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, CFO, CBO & Sec'y","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4954.0,"shares_display":"4,954","price_per_share":7.66,"price_display":"7.66","price_state":"stated","total_value":37947.64,"total_display":"37,947.64","total_whole":"37,948","shares_owned_after":72799.0,"shares_owned_after_display":"72,799","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-17","filed_date":"2023-02-23","scope":"insider"},{"id":6213302,"accession":"0001209191-22-058133","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-058133","line_url":"/filing/0001209191-22-058133#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (CFO, CBO & Secretary)","role_mark":"O","role_mark_label":"Officer (CFO, CBO & Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO, CBO & Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":722.0,"shares_display":"722","price_per_share":5.44,"price_display":"5.44","price_state":"stated","total_value":3927.68,"total_display":"3,927.68","total_whole":"3,928","shares_owned_after":68390.0,"shares_owned_after_display":"68,390","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-18","filed_date":"2022-11-21","scope":"insider"},{"id":6149459,"accession":"0001209191-22-046878","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-046878","line_url":"/filing/0001209191-22-046878#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (CFO, CBO & Secretary)","role_mark":"O","role_mark_label":"Officer (CFO, CBO & Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO, CBO & Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":725.0,"shares_display":"725","price_per_share":14.9608,"price_display":"14.96","price_state":"stated","total_value":10846.58,"total_display":"10,846.58","total_whole":"10,847","shares_owned_after":66693.0,"shares_owned_after_display":"66,693","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-17","filed_date":"2022-08-19","scope":"insider"},{"id":4774257,"accession":"0001209191-21-014517","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-014517","line_url":"/filing/0001209191-21-014517","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (CFO, CBO & Secretary)","role_mark":"O","role_mark_label":"Officer (CFO, CBO & Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO, CBO & Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29642.0,"shares_display":"29,642","price_per_share":33.58618920788071,"price_display":"33.59","price_state":"stated","total_value":995561.8205,"total_display":"995,561.82","total_whole":"995,562","shares_owned_after":71549.0,"shares_owned_after_display":"71,549","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-23","filed_date":"2021-02-25","scope":"insider","n_lines":4},{"id":5284735,"accession":"0001209191-21-000491","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-000491","line_url":"/filing/0001209191-21-000491#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (CFO, CBO & Secretary)","role_mark":"O","role_mark_label":"Officer (CFO, CBO & Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO, CBO & Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":358.0,"shares_display":"358","price_per_share":20.0413,"price_display":"20.04","price_state":"stated","total_value":7174.7854,"total_display":"7,174.79","total_whole":"7,175","shares_owned_after":32500.0,"shares_owned_after_display":"32,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-30","filed_date":"2021-01-04","scope":"insider"},{"id":8661420,"accession":"0001567619-19-009025","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001567619-19-009025","line_url":"/filing/0001567619-19-009025#line-4","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (CBO, CFO and Secretary)","role_mark":"O","role_mark_label":"Officer (CBO, CFO and Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CBO, CFO and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":25.8015,"price_display":"25.80","price_state":"stated","total_value":51603.0,"total_display":"51,603.00","total_whole":"51,603","shares_owned_after":32500.0,"shares_owned_after_display":"32,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-22","filed_date":"2019-04-22","scope":"insider"},{"id":8661414,"accession":"0001567619-19-009025","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-19-009025","line_url":"/filing/0001567619-19-009025#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (CBO, CFO and Secretary)","role_mark":"O","role_mark_label":"Officer (CBO, CFO and Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CBO, CFO and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1073.0,"shares_display":"1,073","price_per_share":25.5111,"price_display":"25.51","price_state":"stated","total_value":27373.4103,"total_display":"27,373.41","total_whole":"27,373","shares_owned_after":32500.0,"shares_owned_after_display":"32,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-18","filed_date":"2019-04-22","scope":"insider"},{"id":7028047,"accession":"0001209191-07-053432","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-07-053432","line_url":"/filing/0001209191-07-053432#line-1","is_derivative":false,"issuer_cik":"0001047188","issuer_name":"PENWEST PHARMACEUTICALS CO","issuer_ticker":"PPCO","issuer_name_source":null,"issuer_url":"/issuer/0001047188","owner_cik":"0001366244","owner_name":"Palleiko Benjamin L","owner_display_name":"Palleiko Benjamin L","owner_url":"/insider/0001366244","role":"Officer (SVP, Corporate Dev. & CFO)","role_mark":"O","role_mark_label":"Officer (SVP, Corporate Dev. & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Corporate Dev. & CFO","security_title":"Common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1500.0,"shares_display":"1,500","price_per_share":10.87,"price_display":"10.87","price_state":"stated","total_value":16305.0,"total_display":"16,305.00","total_whole":"16,305","shares_owned_after":2500.0,"shares_owned_after_display":"2,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-09-14","filed_date":"2007-09-14","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":43,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":42,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":43},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001348911","name":"KalVista Pharmaceuticals, Inc.","url":"/issuer/0001348911","role":"Director, Officer (CHIEF EXECUTIVE OFFICER)","n_filings":38,"first_seen":"2019-04-22","last_seen":"2026-05-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001047188","name":"PENWEST PHARMACEUTICALS CO","url":"/issuer/0001047188","role":"Officer (SVP, Corporate Dev. & CFO)","n_filings":1,"first_seen":"2007-09-14","last_seen":"2007-09-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001366244","retrieved_at":"2026-08-26T16:02:23+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}